## IDXX: IDEXX Laboratories, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 2.0% below STRENGTH zone (4.0-10.0%); PEG 4.00 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($680.79)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. What to Expect From IDEXX Laboratoriesâ€™ Next Quarterly Earnings Report?**
- Source: inkl | 20260105T160819 | Bullish | Relevance: 100%
- IDEXX Laboratories (IDXX) is a multinational healthcare company specializing in diagnostics for animal care and water quality. Analysts anticipate the company will report a profit of $2.93 per share for fiscal Q4 2025, an 11.8% increase year-over-year. The company has consistently exceeded Wall Street's earnings estimates in the past four quarters, and its stock has significantly outperformed the S&P 500 and Health Care Select Sector SPDR Fund over the past year.

**2. Final Trades: Palo Alto Networks, Capital One, Idexx Labs and the XLB**
- Source: CNBC | 20260107T184342 | Neutral | Relevance: 100%
- The "Halftime Report" Investment Committee discussed their top stock picks for the remainder of the trading session. The stocks highlighted included Palo Alto Networks, Capital One, Idexx Labs, and the XLB.

**3. Harbor Health Care ETF Q3 2025 Commentary (MEDI)**
- Source: Seeking Alpha | 20260106T141111 | Somewhat-Bullish | Relevance: 75%
- The Harbor Health Care ETF (MEDI) returned 7.30% (NAV) in Q3 2025, outperforming its benchmark. The fund purchased IDEXX Laboratories, a veterinary services company, due to its strong market position and growth profile, while selling Verona Therapeutics after it reached its price target following an acquisition announcement. MEDI is strategically overweight in biotechnology and underweight in pharmaceuticals, driven by conviction in biotech's innovation and attractive valuations.

**4. Bruker Meets 80-Plus Relative Strength Rating Benchmark**
- Source: Investor's Business Daily | 20260106T161247 | Somewhat-Bullish | Relevance: 62%
- Bruker (BRKR) has achieved a significant performance milestone, with its Relative Strength (RS) Rating climbing to 83, up from 78. This improvement signifies strong market leadership as the RS Rating gauges a stock's price performance over the past 52 weeks compared to other equities. This development indicates an improving technical outlook for Bruker.

**5. Here's Why You Should Retain Masimo Stock in Your Portfolio Now**
- Source: Finviz | 20260105T125100 | Neutral | Relevance: 59%
- Masimo Corporation is expected to see continued growth due to strong demand for its innovative technology and ongoing R&D efforts, reinforced by a solid third-quarter 2025 performance and product portfolio. Despite concerns about overreliance on its SET unit and reimbursement challenges, the company has consistently surpassed earnings estimates. Strategic partnerships and advancements in intelligent monitoring and wearables are key drivers for future growth.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $850 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($2.08M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+0.9%)
- Blackrock Inc.: 10.3% (-2.0%)
- State Street Corpora: 4.4% (-1.0%)
- Fundsmith LLP: 3.3% (-1.1%)
- Geode Capital Manage: 3.1% (+1.4%)

### Key Risks

1. Valuation stretched: PEG 4.0x requires aggressive growth execution.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +4.6% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 4.00 signals overvaluation risk, limited margin of safety. Forward P/E 49.6x stretched relative to 12% growth. Quality metrics strong (ROE 65%, ROA 24%, margin 25%). Insider buying signal ($2.1M), management confidence. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $57.2B |
| Beta | 1.67 |
| 52W Range | $356.14 - $769.98 |
| Short Interest | 3.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.00 |
| Forward P/E | 49.6 |
| Current P/E | 55.4 |
| YoY Growth | 11.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -2.6% to 2.0% (+4.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.0pp (needs >4.0% for momentum thesis). MRS_5 at 2.8% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.22), confirming momentum. RSI neutral at 59. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.99% (CS: 70) | Neutral |
| RSI_14 | 58.7 | Neutral |
| MACD Histogram | 1.22 | Bullish |
| vs SMA20 | 1.030x | Above |
| vs SMA50 | 1.022x | Above |
| vs SMA200 | 1.218x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $714.55
- **Stop Loss:** $680.79 (4.7% risk)
- **Target:** $748.31 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 35
- **Position Value:** $25,009.25
- **Portfolio %:** 25.01%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk appetite. VIX at 15.38 sits in the normal range (18th percentile of 52-week) with modest upward drift, while yield curve remains positively sloped (+62bps 10Y-3M) supporting risk assets. Breadth at 59.5% shows healthy participation, though elevated put/call ratio (1.12) suggests some hedging activity. FOMC 20 days out provides runway for current conditions to persist.*

### Earnings

**Next:** 2026-02-03 (Est: $2.93)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.14 | $3.40 | +8.3% |
| 2025Q2 | $3.30 | $3.63 | +10.0% |
| 2025Q1 | $2.85 | $2.96 | +3.9% |
| 2024Q4 | $2.40 | $2.62 | +9.0% |

---
*RULE-based L3 | 2026-01-08 08:02 | MRS_20*